+91 9425150513 (Asia) support@24lifesciences.com
Size, Share & Industry Analysis, By Product Type (Disposable Automatic Biopsy Guns, Reusable Automatic Biopsy Guns), By Application (Breast Biopsy, Prostate Biopsy, Lung Biopsy, Liver & Kidney Biopsy, Lymph Node & Other Lesions), By End User (Hospitals, Diagnostic & Imaging Centers, Ambulatory Surgical Centers, Specialty Clinics), and Regional Forecast, 2026-2034
The global Automatic Biopsy Gun market was valued at USD 782.6 million in 2025 and is estimated at USD 827.2 million in 2026. The market is projected to reach USD 1.29 billion by 2034, exhibiting a 5.7% CAGR during 2026–2034.
Automatic biopsy guns are spring-loaded or mechanically actuated core-needle devices designed to rapidly advance a stylet and cutting cannula into soft tissue to obtain histologic specimens. They are used under ultrasound, CT, stereotactic or other imaging guidance for breast, prostate, liver, kidney, lung, lymph-node and other soft-tissue biopsies. The category includes disposable fully automatic biopsy devices and reusable automatic guns used with compatible disposable needles.
The clinical value proposition is procedural consistency. Automatic firing controls throw length and sample-notch capture, reducing variability compared with purely manual advancement. Merit Medical's Achieve platform provides automatic, delayed and zero-throw modes, while BD's Marquee disposable instrument offers automatic firing with selectable 18 mm or 25 mm penetration depth. These features are designed to improve control near vessels, pleura and other structures where precise needle movement matters.
Core biopsy remains essential to tissue diagnosis because pathology and molecular testing often require intact tissue architecture rather than cytology alone. Rising use of image-guided percutaneous biopsy, outpatient interventional radiology and targeted oncology diagnostics supports recurring demand for sterile disposable biopsy guns and compatible coaxial introducers.
The study covers fully and semi-/programmable automatic soft-tissue biopsy guns and systems used for image-guided core tissue acquisition.
| Report Attribute | Coverage |
|---|---|
| Base Year | 2025 |
| Estimated Year | 2026 |
| Forecast Period | 2026–2034 |
| Market Measurement | Revenue, USD million/billion |
| By Product Type | Disposable Automatic Biopsy Guns; Reusable Automatic Biopsy Guns |
| By Firing Mode | Fully Automatic; Programmable / Delayed Automatic; Other Configurations |
| By Application | Breast Biopsy; Prostate Biopsy; Lung Biopsy; Liver & Kidney Biopsy; Lymph Node / Other Soft Tissue |
| By Guidance | Ultrasound-Guided; CT-Guided; Stereotactic / X-ray Guided; MRI-Compatible Systems |
| By End User | Hospitals; Diagnostic / Imaging Centers; Ambulatory Surgical Centers; Specialty Clinics |
| By Region | North America; Europe; Asia-Pacific; Latin America; Middle East & Africa |
| Key Market Players | BD; Merit Medical Systems; Argon Medical Devices; IZI Medical Products; M?ller Medical; Geotek Medical; M.D.L. S.r.l.; Sterylab; Mammotome |
Breast, prostate, lung, liver, kidney and lymph-node lesions frequently require tissue confirmation before therapy selection. Core biopsy can provide histology and material for immunohistochemistry or molecular testing, supporting demand throughout oncology pathways.
Percutaneous core biopsy can often be performed with local anesthesia and imaging guidance, reducing recovery time compared with open surgical biopsy. This supports automatic-device use in interventional radiology, breast centers and outpatient settings.
Single-use automatic devices are sterile and eliminate cleaning, sterilization and mechanical wear between patients. Merit and IZI explicitly position current automatic systems as single-use devices, supporting hospital standardization around disposable products.
Delayed firing, zero-throw modes and adjustable penetration depths allow the clinician to verify needle position before final tissue capture. These functions are particularly valuable when lesions are close to pleura, vessels or other vulnerable anatomy.
Automatic biopsy guns are mechanically simpler than capital imaging equipment, and regional manufacturers can compete aggressively on unit price. Established suppliers defend share through reliability, breadth of gauge/length options, imaging visibility and hospital distribution.
Automatic, delayed and zero-throw modes let one device address different tissue targets and safety considerations. This expands product utility without requiring multiple separate biopsy devices.
Coaxial introducers permit repeated sampling while reducing repeated skin and tissue punctures. This is useful when multiple cores are needed for pathology, biomarkers or heterogeneous lesions.
Current breast-procedure portfolios increasingly combine tissue acquisition with localization, site marking and multimodality imaging compatibility. Integrated workflows can improve patient throughput and strengthen supplier relationships with breast centers.
FDA listings include MRI and conventional fully automatic biopsy sets, while breast-biopsy manufacturers continue to develop in-room MR solutions. MRI compatibility creates a specialized premium segment.
Rising cancer detection, imaging capacity and private hospital investment across China, India and Southeast Asia are expanding the addressable biopsy procedure base, favoring both global and local device manufacturers.
Product performance depends on firing mechanics, needle geometry, throw length, imaging visibility, sterility and compatibility with coaxial access.
| Technology Feature | Clinical Role | Market Relevance |
|---|---|---|
| Automatic spring-loaded firing | Rapidly advances stylet and cannula to capture a tissue core. | Core defining technology; improves repeatability. |
| Delayed firing mode | Advances or exposes the sample notch before cutting so location can be verified. | Important for precise image-guided targeting. |
| Zero-throw / controlled throw | Reduces or limits forward needle excursion during final capture. | Supports safety near sensitive structures. |
| Echogenic needle markings | Improve ultrasound visualization of needle tip and sample notch. | Key purchasing feature in ultrasound-guided biopsy. |
| Coaxial introducer | Provides a stable tract for multiple tissue samples from one puncture. | Supports multi-core pathology and molecular analysis. |
| Disposable sterile configuration | Single-patient-use device supplied ready for the procedure. | Largest commercial configuration and recurring revenue driver. |
Disposable automatic biopsy guns represent the leading configuration, while reusable guns retain a smaller niche where institutions prefer durable handles with disposable needles.
Sterile single-use automatic guns reduce reprocessing burden and offer consistent firing performance. BD Marquee, Merit Achieve, IZI Quick-Core Auto and M?ller ABG illustrate the breadth of current disposable options.
Reusable systems such as M?ller Medical Blue use a durable firing handle with dedicated disposable needles. Their economics can be attractive in high-volume centers but require validated cleaning, sterilization and maintenance.
Breast biopsy leads the market, while prostate, lung, liver, kidney and other soft-tissue applications create a diversified procedural base.
Image-detected breast abnormalities frequently require histologic confirmation. Automatic guns are widely used for ultrasound-guided core biopsy and can integrate with breast localization workflows.
Automatic firing and one-handed operation support transrectal or transperineal biopsy workflows. Dedicated URO needle variants are available from suppliers such as Argon.
CT-guided lung biopsy requires precise throw control because lesions may be near pleura or vessels. Lightweight guns and controlled firing modes can reduce unwanted movement.
Core biopsy supports oncology, nephrology and hepatology diagnosis. Coaxial access can enable multiple samples through one tract.
Automatic devices are also used for spleen, thyroid, lymph-node and miscellaneous soft-tissue masses depending on labeling and clinical judgment.
Hospitals are the largest end-user group because they concentrate interventional radiology, surgery, urology and oncology services. Diagnostic and breast-imaging centers are important high-throughput users.
Hospitals purchase broad gauge/length ranges and maintain contracts across interventional radiology, breast, urology and surgery. Standardization and sterile availability are key procurement factors.
Independent imaging centers perform ultrasound- and CT-guided biopsies and emphasize one-handed operation, predictable sample quality and efficient scheduling.
ASCs support selected prostate, breast and soft-tissue procedures where minimally invasive diagnostics can be performed without inpatient admission.
Breast, urology and oncology clinics represent a smaller but important channel, especially where in-office ultrasound-guided biopsy is common.
North America is the largest regional market, accounting for about 42% of 2025 revenue. The United States combines high cancer-screening intensity, extensive image-guided biopsy capacity, strong pathology and molecular-testing infrastructure, and broad use of disposable interventional devices.
Europe is a mature biopsy-device market with strong hospital radiology networks and established breast- and prostate-diagnostic pathways. Device procurement emphasizes CE/MDR compliance, sterility, ergonomic design and tender economics.
Asia-Pacific is the fastest-growing major region. China, India, Japan and South Korea are expanding imaging, cancer diagnosis and interventional radiology. Regional manufacturing also increases price competition and device availability.
Brazil and Mexico lead regional demand through expanding oncology and imaging services. Growth is concentrated in urban hospitals and private diagnostic centers, with import pricing and distributor support influencing adoption.
Gulf countries support premium interventional devices in advanced hospitals, while broader African demand remains constrained by imaging and pathology capacity. Long-term growth follows expansion of cancer diagnostics and minimally invasive procedures.
Automatic biopsy instruments are Class II devices in the United States and are subject to performance, sterility, biocompatibility and labeling requirements.
| Regulatory / Safety Element | Current Position | Market Effect |
|---|---|---|
| FDA 21 CFR 876.1075 | Biopsy instruments are Class II devices under product code KNW. | Creates an established 510(k) pathway. |
| FDA-cleared automatic devices | K223300 covers multiple automatic biopsy needle and gun configurations. | Confirms modern fully automatic designs across common gauges. |
| Single-use sterility | Merit Achieve and IZI Quick-Core Auto are supplied for single use. | Supports infection-control and recurring device revenue. |
| Image-guided use | Current devices are designed for ultrasound and/or CT guidance; specialized products support MRI environments. | Imaging compatibility is a key differentiator. |
| Needle throw control | Current platforms offer automatic, delayed and zero-throw or adjustable-depth options. | Improves procedural precision and safety positioning. |
Competition combines multinational interventional-device suppliers with specialist biopsy manufacturers. Product portfolios, hospital contracts, gauge breadth and reliable sterile supply are major competitive advantages.
Merit markets Achieve, Pink Achieve, CorVocet and TEMNO-related biopsy systems across breast, lung, liver, kidney and other procedures. Achieve's three firing modes differentiate its automatic platform.
BD's Marquee disposable core biopsy instrument provides automatic firing and adjustable penetration depth, supported by broad hospital distribution.
Argon's Tru-Core II provides one-handed automatic biopsy with a 22 mm throw, echogenic tip and URO variants for prostate applications.
Quick-Core Auto offers automatic, delay and zero-throw modes across multiple gauges and lengths, with single-use sterile supply.
M?ller Medical offers disposable automatic biopsy guns and reusable automatic platforms with compatible needles, including low-noise and one-handed designs.
A broad set of regional suppliers competes on price, needle configuration, MRI compatibility and distributor relationships.
18 March 2026: Mammotome received FDA clearance for its Prima MR in-room vacuum-assisted breast biopsy system and HydroMARK Plus MR marker, highlighting continued investment in MRI-guided breast biopsy workflows adjacent to automatic core biopsy.
2026 current portfolio: Merit Medical continues to market the Achieve programmable automatic biopsy device with automatic, delayed and zero-throw firing modes and optional coaxial access.
2026 current portfolio: BD's Marquee disposable core biopsy instrument remains available with automatic firing and selectable 18 mm or 25 mm penetration depth.
2026 FDA database: FDA's current registration and listing database includes fully automatic biopsy guns, MRI/conventional fully automatic biopsy sets and related automatic systems under Class II biopsy instrument classification.
The global Automatic Biopsy Gun market is projected to grow from USD 827.2 million in 2026 to USD 1.29 billion by 2034, at a 5.7% CAGR. Growth will be supported by cancer diagnostics, image-guided outpatient biopsy, disposable-device adoption and increasing demand for controlled firing and coaxial sampling.
| Forecast Variable | Current Direction | Expected Effect Through 2034 |
|---|---|---|
| Cancer diagnostic volume | Biopsy remains central to tissue diagnosis and biomarker testing. | Supports recurring procedure growth. |
| Disposable devices | Hospitals favor sterile single-use workflows. | Increases recurring unit demand. |
| Imaging guidance | Ultrasound and CT capacity continues to expand. | Broadens procedure access. |
| Programmable firing | Multi-mode systems improve control near sensitive structures. | Supports premium product mix. |
| Asia-Pacific expansion | Cancer imaging and interventional radiology are growing quickly. | Creates strongest incremental unit growth. |
The study supports biopsy-device strategy, procurement, product development, distributor planning and competitive benchmarking.
Market sizing combines bottom-up supplier, product, pricing and utilization analysis with top-down demand validation. Quantitative inputs include procedure or research volumes, product configuration, replacement and replenishment cycles, end-user mix, regional infrastructure, pricing and adoption of newer technologies.
Primary research validates purchasing criteria, workflow requirements, adoption barriers and competitive positioning. Secondary research prioritizes regulators, public-health agencies, professional bodies, peer-reviewed literature and official manufacturer information. Forecast assumptions are cross-checked against regulatory activity, technology development, healthcare or R&D investment and regional capacity expansion.
Forecasts incorporate soft-tissue biopsy procedure growth, disposable-versus-reusable mix, average selling prices, gauge and length mix, image-guided procedure penetration, hospital and diagnostic-center demand, and regional oncology infrastructure. Growth assumptions are strongest in disposable automatic systems and Asia-Pacific procedure volumes, while mature-market growth is weighted toward replacement, standardization and premium programmable devices.
The market was valued at USD 782.6 million in 2025 and is estimated at USD 827.2 million in 2026. It is projected to reach USD 1.29 billion by 2034, representing a 5.7% CAGR.
Disposable automatic biopsy guns lead because they are supplied sterile, reduce reprocessing requirements and create predictable single-procedure use.
Breast biopsy is the largest application, supported by high screening volumes and widespread use of ultrasound-guided core tissue sampling.
North America leads with approximately 42% of 2025 revenue, supported by advanced imaging and pathology infrastructure.
FDA classifies biopsy instruments under 21 CFR 876.1075 as Class II devices, commonly using product code KNW and the 510(k) pathway.
Key features include programmable firing, delayed firing, zero-throw or adjustable penetration depth, echogenic markings, coaxial access and one-handed operation.
The report profiles BD, Merit Medical, Argon Medical, IZI Medical, M?ller Medical, Geotek, M.D.L., Sterylab and Mammotome.
The public overview uses 2025 as the base year, 2026 as the estimated year and 2026–2034 as the forecast period.
Display logos only where use is approved. A logo does not imply a public endorsement.
The data provided by 24LifeScience was clear, well-organized, and useful for internal strategy planning. It helped us understand the competitive landscape more effectively.
We used one of their market overview reports for early-stage feasibility work. It gave us a helpful snapshot of current trends and key players in our therapeutic area.
I appreciated the team’s responsiveness and willingness to adjust the scope based on our feedback. The final report was aligned with our expectations and timelines.
Their custom report on clinical trial trends was a helpful reference as we explored new indications.
As someone working on early product planning, I found their therapeutic-area briefs useful and easy to apply in our internal discussions.
We needed dependable data and a clearly presented market structure. The research gave us a practical starting point for our assessment.
Publish named testimonials only when the individual and organization have approved disclosure.
Review the report scope, forecast timeframe, methodology, and cited evidence before deciding whether the full study fits your requirement.
Coverage, segmentation, geography, and market boundaries are stated within the report.
Readers can review the published sources and evidence referenced in this market overview.
Base, estimated, and forecast years are shown to place the market outlook in context.
Each overview displays its report identifier and latest update date.
A structured view of market size, forecast outlook, segmentation, regional dynamics, competitive activity, and the research framework behind this study.
Review the market estimate, growth outlook, forecast direction, and key factors influencing future demand.
Understand the report’s defined segments, demand drivers, applications, end users, and market opportunities.
Assess regional performance, selected country context, and factors shaping adoption across major markets.
Explore company profiles, market positioning, and selected developments relevant to the market landscape.
Review key demand drivers, challenges, emerging opportunities, technology shifts, and factors influencing market direction.
Understand the report scope, market boundaries, research approach, and evidence referenced in the published market overview.
